QNCX Stock Overview
A biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Quince Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.02 |
| 52 Week High | US$2.45 |
| 52 Week Low | US$0.51 |
| Beta | 0.71 |
| 11 Month Change | 87.04% |
| 3 Month Change | 208.16% |
| 1 Year Change | 120.33% |
| 33 Year Change | -84.47% |
| 5 Year Change | -92.87% |
| Change since IPO | -93.86% |
Recent News & Updates
Recent updates
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
Aug 20Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation
Nov 21
Cortexyme to change name and ticker symbol next month
Jul 27Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
Mar 01Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
Dec 15We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
Dec 15Cortexyme: A Challenging Path Forward
Nov 17Cortexyme: Positive Lessons To Be Learned From Disappointing Results
Nov 01Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
Oct 11Cortexyme: Alzheimer's Readout In November A Binary Event
Sep 12We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth
Aug 23Cortexyme EPS beats by $0.02
May 10We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
May 10Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares
Mar 10Shareholder Returns
| QNCX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.1% | 4.0% | 2.2% |
| 1Y | 120.3% | 18.3% | 32.6% |
Return vs Industry: QNCX exceeded the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: QNCX exceeded the US Market which returned 32.6% over the past year.
Price Volatility
| QNCX volatility | |
|---|---|
| QNCX Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QNCX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QNCX's weekly volatility has increased from 12% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 32 | Dirk Thye | www.quincetx.com |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.
Quince Therapeutics, Inc. Fundamentals Summary
| QNCX fundamental statistics | |
|---|---|
| Market cap | US$87.12m |
| Earnings (TTM) | -US$53.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs QNCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QNCX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$53.26m |
| Earnings | -US$53.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 33.2% |
How did QNCX perform over the long term?
See historical performance and comparison